Issue link: http://osercommunicationsgroup.uberflip.com/i/709458
C h a i n D r u g s t o r e D a i l y 8 5 Tu e s d a y, A u g u s t 9 , 2 0 1 6 deactivation pouches, providing a secure, convenient and environmentally safe way to dispose of unused medica- tions. These pouches deactivate drugs and render chemical compounds safe for landfills. "As a company focused on patients and communities, Mallinckrodt has long been a strong advocate of addressing the complex issues of opioid misuse and abuse," said Mark Trudeau, Mallinckrodt President and Chief Executive Officer. "Providing a safe, environmentally responsible way to dispose of unused medications is critical in this fight against prescription drug abuse. Mallinckrodt is committed to working with policy mak- ers, community leaders, law enforcement and industry partners to ensure the responsible use of pain medication and prevent unused medications from ending up in the wrong hands." The company will distribute the pouches through collaboration with poli- cy champions and community leaders. For example, in the home state of its Specialty Generics business the company provided 250,000 systems to ACT Missouri, through its Missouri Substance Abuse Prevention Network's community coalitions that will work with educators, pharmacies, law enforcement and mental health providers to distribute the pouches. "With Mallinckrodt's support, we can further our mission to serve as the statewide prevention catalyst, empower- ing individuals and fostering partnerships to promote safe, healthy and drug-free communities," said Chuck Daugherty, Executive Director of ACT Missouri. "This partnership will help ensure the safe use and proper disposal of prescrip- tion medications for Missouri families." Nearly 68 percent of those who used prescription pain relievers non-medically in 2012-2013 got them from friends or Mallinck ro dt (C o nt'd. fro m p. 1 ) relatives, according to the 2013 Substance Abuse and Mental Health Services Administration (SAMHSA) National Survey on Drug Use and Health. Mallinckrodt has made past pouch donations to providers, patient groups and other stakeholders through partner- ships with organizations such as Community Anti-Drug Coalitions of America (CADCA) and The Jed Foundation and ACT Missouri. These donations are part of the com- pany's multi-million dollar investments in a comprehensive effort to address opi- oid abuse and misuse. An integral part of Mallinckrodt's vision is to invest in and expand the use of opioid abuse-deterrent technology. Other elements include: improving integration of federal and state prescription drug monitoring programs (PDMPs) and efforts – and Mallinckrodt has strongly advocated for Missouri PDMP; developing and sharing best practices for monitoring suspicious orders, both at the manufacturing and supply chain stages; improving stake- holder education for patients, providers and the public at large, including educa- tion initiatives validated by measurable outcomes; and enhancing drug take-back and addiction rehabilitation programs. "Substance abuse is arguably the greatest public health crisis facing the U.S. today," said CADCA Chairman and Chief Executive Officer Gen. Arthur T. Dean. "Addressing our nation's misuse of pain medication requires collaboration and com- mitment from every sector. We commend Mallinckrodt for their efforts to make drug disposal safer and easier for patients, and we welcome the opportunity to collaborate with Mallinckrodt and others on these types of industry-led initiatives." Visit Mallinckrodt Pharmaceuticals at booth #171. For more information, call 800.325.8888 or go to www .mallinckrodt.com. all hospitalizations and results in 125,000 deaths. C. Everett Koop was right when he said, "Drugs don't work in patients who don't take them." The dilemma remains: how do phar- macies contribute to increasing patient adherence in an efficient manner that does not send costs through the roof? Pharmacies have relied heavily on auto- mated patient communications, including inbound IVR, outbound notifications, web/mobile applications, MedSync and scheduling solutions for immunizations and screenings. However, employing multiple vendors can cause confusion for patients, additional work for pharmacy staff and the potential for violations of the FCC TCPA and FTC TSR regulations. MarkeTouch Media is the only U.S. vendor in the industry that provides holistic patient communication services and without utilizing third party vendors or outsourced programmers. The bene- fits of using MarkeTouch's RxTouch suite of services include: consistent scripting, voices and interfaces for com- municating with patients; a single portal, allowing pharmacy staff to view all patient communication and reporting through one URL; and a single vendor, reducing security concerns related to data transmissions. Mark eTo uch Media (C o nt'd. fro m p. 1 ) In addition to providing consistent messaging through automation, pharma- cies are increasing personal communica- tion between staff and patients. In its annual report card, NCPA determined that "the leading indicator of whether a patient will adhere to their medication is their personal relationship with the phar- macist or pharmacy staff." MarkeTouch's unique service, Pharmacist Connect, allows pharmacy staff to increase patient communication without affecting workflow. A pharmacy staff member logs in to the portal (the same, single portal used for automated messaging); views patient history, med- ications, adherence information and potential interventions; and makes calls without dialing the phone. The service has proven to increase patient adherence to their medication regimens; results include Return to Stock reduced by 20 percent over traditional automation, increasing PDC scores by 30 percent and more than 50 percent enrollment into MedSync. It's clear that a single source for all patient communications increases phar- macy revenue, patient adherence and sat- isfaction. Visit MarkeTouch Media at booth #421. For more information, go to www.rxtouch.com. ADHD may be prone to careless mis- takes, be easily distracted and forgetful. They may have trouble sitting still or staying quiet. These behavioral problems can become challenges for patients, their families and their teachers. Due to educational efforts on the part of government organizations, not- for-profit advocacy groups and pharma- ceutical companies, the general public and the medical community is becoming more aware of this common condition. In an analysis of parent-reported data, the National Health Interview Survey (NHIS) 2011-2013 found that 9.5 percent of children ages 4-17 years have been diagnosed with ADHD. That's 13.3 per- cent of boys and 5.6 percent of girls in this age group in the United States. ADHD diagnosis increased from 7.0 per- cent in 1997-1999 to 10.2 percent in 2012-2014. More than 75 percent of these children will have symptoms as adults. As part of a large and growing glob- al pharmaceutical company with a strong focus on specialty products, Lupin Pharmaceuticals, Inc. is committed to helping ADHD patients manage their condition. With U.S. headquarters in Baltimore, the company delivers high- quality, branded and generic medications L upin (C o nt'd. fro m p. 1 ) trusted by healthcare professionals and patients. "When children are diagnosed with ADHD, it's important that parents and care providers have access to affordable and effective treatments. That's why we're focused on developing new and improved therapies in ADHD treatment and management, and ensuing they are accessible to patients," noted Jay Liska, Lupin's Director of Marketing for Specialty Products. "We also offer a vari- ety of educational materials for ADHD patients, their families and healthcare providers." Lupin works with pediatric psychia- trists and pediatricians across the country to help care for the growing population of ADHD patients and their families. The company is also a sponsor of Children and Adults with Attention- Deficit/Hyperactivity Disorder (CHADD), a non-profit organization dedicated to improving the lives of peo- ple with ADHD. Lupin continues to strive for excel- lence in supporting ADHD patients, their families and healthcare professionals with affordable, effective medications and helpful educational resources. Visit Lupin Pharmaceuticals at booth #824. For more information, go to www.lupinpharmaceuticals.com. continue to grow. What should retail pharmacies do? Determine status, goals and invest- ment. Pharmacies should measure themselves and identify opportunities through internal solutions, EQUIPP and contract management solutions, apply- ing pharmacy level benchmarking with- in their chain and the industry overall. They should accurately forecast DIR and account for it as a sales adjustment, quantify the financial value of improve- ment to justify investment and evaluate solutions and their successes against their investment ability, considering some programs are offered in coordina- tion with the plans, some are funded by pharma and/or plans, and that patient engagement will increase front store sales. Align patient needs with appropri- ate solutions and demonstrate success to the plans. Pharmacies must experiment with solutions. Start low-tech and evolve as needs and success grows: refill reminders/automated refill solu- tions like IVR, e-mail, mobile apps, etc.; Med Sync, MTM in-house or through I nmar (C o nt'd. fro m p. 4 ) partners; proactive phone outreach; pro- motional programs, Rx coupons, med- ication assistance to help with the cost of care; telemedicine appointments or in-person in the pharmacy. They should communicate with plan partners rou- tinely; prepare in advance by under- standing contract responsibilities and goals, developing a plan to reach patients/members with opportunities, and understanding current performance and areas where opportunity for improvement lies; and discuss with them how patient-facing staff will address opportunities and how they are aware their performance. Do you have the tools in place to know where you are today? Inmar's Contract Management solution can help you be more successful in value-based reimbursement through measuring quali- ty at the contract level, forecasting DIR fees, modeling the financial upsides and downsides of different scenarios and pin- pointing which patients need what serv- ices. Visit Inmar at booth #1949. For more information, call 866.440.6917 or email solutions@inmar.com. noticed it leaving. Not only that – I felt completely refreshed, my head was so clear, and I was not tired. I thought, "This is a miracle!" It has now been more than three years that I have used Mycratine on a regular basis, and it is nearly always as effective as the first time I took it. Mycratine (C o nt'd. fro m p. 4 ) Mycratine helps balance my brain chem- istry, so that everything settles down and the migraine effect is gone, always with- in 15 minutes. Thank you, Mycratine, for continu- ing to supply me with this wonderful remedy. I hope to see more people start using and benefiting from Mycratine. Visit Mycratine at booth #2363.